Clinical Trial Update: Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing XL092 plus atezolizumab versus regorafenib in metastatic colorectal cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Regorafenib (regorafenib)
• XL092

Snippet

Sponsor: Exelixis | Conditions: Colorectal Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING